Redmile Group LLC Takes $3.42 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Redmile Group LLC purchased a new position in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 310,884 shares of the biotechnology company's stock, valued at approximately $3,423,000. Redmile Group LLC owned 0.55% of Astria Therapeutics as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the stock. FMR LLC boosted its holdings in Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company's stock worth $86,123,000 after purchasing an additional 1,767,714 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Astria Therapeutics by 23.1% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company's stock worth $44,040,000 after buying an additional 750,000 shares during the last quarter. Nantahala Capital Management LLC purchased a new position in shares of Astria Therapeutics in the 2nd quarter worth $6,142,000. Vanguard Group Inc. grew its holdings in shares of Astria Therapeutics by 23.4% in the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company's stock worth $35,693,000 after acquiring an additional 480,184 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new stake in Astria Therapeutics during the second quarter valued at $2,561,000. 98.98% of the stock is owned by hedge funds and other institutional investors.

Astria Therapeutics Trading Down 3.8 %

Astria Therapeutics stock traded down $0.39 during midday trading on Thursday, hitting $9.75. The stock had a trading volume of 1,292,169 shares, compared to its average volume of 600,524. Astria Therapeutics, Inc. has a 52-week low of $4.87 and a 52-week high of $16.90. The firm's fifty day moving average is $11.01 and its two-hundred day moving average is $10.65.

Analysts Set New Price Targets

ATXS has been the subject of a number of recent research reports. Evercore ISI upgraded Astria Therapeutics to a "strong-buy" rating in a research note on Wednesday, August 14th. Oppenheimer boosted their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an "outperform" rating in a research report on Thursday, November 14th. HC Wainwright reaffirmed a "buy" rating and set a $16.00 target price on shares of Astria Therapeutics in a report on Thursday, November 14th. Finally, Wedbush reiterated an "outperform" rating and set a $22.00 price target on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Astria Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $25.60.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.